Liver cancer patients get a second chance with combo drug add-on
NCT ID NCT07184424
First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 26 times
Summary
This study tested whether adding lenalidomide could help people with advanced liver cancer whose tumors kept growing despite standard treatment with lenvatinib and immunotherapy. Researchers tracked 24 patients to see how long they lived without the cancer getting worse. The goal was to find a way to control the disease when the first treatment fails.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Tsinghua Changgung Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.